Hizentra FDA Approval History
FDA Approved: Yes (First approved March 4, 2010)
Brand name: Hizentra
Generic name: immune globulin subcutaneous (human)
Dosage form: Liquid
Company: CSL Behring
Treatment for: Primary Immunodeficiency Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Hizentra (immune globulin subcutaneous (human)) is an immune globulin indicated for the treatment of primary immunodeficiency, and for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.
Development timeline for Hizentra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.